32 results about "Macular disease" patented technology

The invention relates to a blue-ray-level protective resin lens with the refraction index of 1.67. The blue-ray-level protective resin lens with the refraction index of 1.67 comprises a resin substrate with the refraction index of 1.67; the resin substrate is dip-coated with a hardened film; a first SiO2 film, a ZrO2 film, a second SiO2 film, a Ti2O3 film, an In2O3 film and a third SiO2 film are deposited on the surface of the hardened film in sequence. According to the resin lens disclosed by the invention, the effect of filtering blue rays with the wavelength of 400 to 500 nm can reach 45 to 50 percent; blue ray radiation can be filtered effectively; sharp pain, soreness and swelling of eyes can be reduced; eye dryness and eye fatigue can be reduced; cataract and macular degeneration can be prevented.

A method for treating diseases selected among cancer, coronary disease, inflammatory disease and macular disease by chelation therapy is disclosed.

The invention discloses lutein effervescent tablets for prevention and treatment of retinal macular degeneration and a preparation method thereof. Through scientific proportion of water-soluble lutein and zeaxanthine and through prescription screening, the weight percentage of the lutein with an antioxidant effect is determined to be 0.2-20%, and the weight percentage of auxiliary materials is determined to be 80-99.8%. Each sheet of the antioxidant lutein effervescent tablets preferably contains 2-20 mg of the lutein with the antioxidant effect. The ratio of the lutein with the antioxidant effect to zeaxanthine is 2:1. The novel effervescent preparation which is easy to store and carry, rapid in disintegration, convenient to take, fast in acting and high in bioavailability is obtained.

The invention discloses a lutein ester tablet candy and a preparation method thereof, and belongs to the technical field of health food processing. The product of the invention is prepared by the following raw materials by weight: 13-17 parts of extract, 12-18 parts of maltodextrin, 65-75 parts of sugar powder, 0.02-0.05 part of lutein ester, 0.3-1 part of magnesium stearate. The preparation process comprises cleaning, soaking, decoction, concentration, granulation, drying, total mixing, and tabletting. The extract is decocted according to the following formulae: (1) 2-6 parts of medlar, 1-5 parts of mulberry, 3-7 parts of Chinese yam, and 4-6 parts of red dates; (2) 7-10 parts of medlar, 2-5 parts of florists chrysanthemum, 3-7 parts of Chinese yam, 2-6 parts of poria cocos, and 4-8 parts of licorice; (3) 8-12 parts of lily, 13-17 parts of Chinese yam, 18-22 parts of coix seeds, and 8-12 parts of red dates. The product of the invention has the effects of nourishing liver and improving eyesight, preventing dry eyes, preventing and treating age-related macular diseases and cataract, nourishing kidney and invigorating spleen, nourishing stomach, and the like.

Provided herein are methods and systems to screen for subjects at risk for retinal-associated eye diseases or to monitor the progression/regression thereof. Generally, the method comprises simultaneously or sequentially displaying to a potentially at-risk individual targets of parallel and nonparallel lines, obtaining an orientation discrimination threshold based on the subject's selections and correlating an increase in the threshold compared to that of a normal control or to a previous threshold measured for the subject as indicative of risk for a retinal-associated eye disease or a progression of the eye disease. Also provided are program storage devices and computer program products effective to store instructions or source code to perform the methods.

The invention discloses a GA lesion segmentation method based on depth-concatenated model for SD-OCT images. The method comprises steps of three kinds of depth network models with different layers arefirstly configured; The first layer is the input layer, the last layer is the output layer, and the middle layer is a sparse self-encoder with different number of neurons, and the encoding and decoding process are symmetrically distributed. The training is divided into two stages, self-supervised feature extraction stage and supervised-based classifier training stage. After the first stage training is completed, the first stage coding process is added with soft-max loss function training basic classifier inputs the labeled positive and negative samples with h-dimension characteristics into the depth network model, and trains the output layer of the soft-max classifier obtains the final segmentation result. Finally, based on Adaboost cascade strategy, the training process of the above model is fused to improve the final segmentation results. This method improves the segmentation accuracy of GA lesions and is of great significance for the prevention and diagnosis of macular diseases inthe elderly.

Apparatus for treating age-related macular degeneration, the apparatus comprising a light source which, in operation, serves to emit a therapeutic light beam presenting an emission wavelength lying in the range 1.2 μm to 1.3 μm, and preferably equal to 1.26 μm to 1.27 μm. The laser source preferably comprises an optical fiber Raman laser.

The invention relates to a blue-light-resistant resin lens of 1.60 in refractivity. The blue-light-resistant resin lens comprises a resin substrate of 1.60 in refractivity, a hardened film layer is dipcoated on the resin substrate, and a first SiO2 film layer, a ZrO2 film layer, a second SiO2 film layer, a Ti2O3 film layer, an In2O3 film layer and a third SiO2 film layer are sequentially deposited on the surface of the hardened film layer. The blue-light-resistant resin lens can filter 40-50% of blue light of 400-500nm in wavelength and can effectively filter blue light radiation, pricking and soreness of eyes can be reduced, eye dryness and eye fatigue can be reduced, and cataract and maculopathy can be prevented.

Apparatus and methods to improve the vision in a person with a macular disease, comprising the purposeful temporary creation of increased corneal optical aberrations. Strategies include corneal treatment patterns that are one or more of asymmetric, decentered or eccentric with respect to the visual axis, which would result in worsening vision in a normal eye but surprisingly become sight enhancing in a patient with the loss of foveal function due to macular disease.

The invention relates to the technical field of biology, and particularly discloses application of a small molecule compound composition in preparation of a medicine for preventing and treating retinal injury diseases. The small molecule compound composition effectively antagonizes cell death and dysfunction caused by oxidative stress on retinal pigment epithelial cells, and can effectively protect the retinal pigment epithelial cells so as to protect the structural integrity and normal function of the whole retinal layer cells; the compound can be used for preventing and potentially treating retinal injury caused by oxidative stress, and is particularly favorable for preventing and/or treating age-related maculopathy and other retinal injury diseases. Besides, experiments prove that the small molecule compound composition has no obvious pharmacological toxicity and can effectively control occurrence and development of retinal injury diseases, and a new theoretical support is provided for development of unknown biological activity and future clinical treatment effects of the small molecule compound composition.

The invention discloses a production formula and a production method of blueberry lutein soft sweets, and belongs to the technical field of soft sweets preparation. The production formula and the production method of the blueberry lutein soft sweets are characterized in that in the step S1, according to the ingredient table, each 100 kg of the blueberry lutein soft sweets comprises, by mass, 8-15% of water, 40-60% of maltitol liquid, 30-40% of maltitol powder, 3-6% of isomaltose sugar alcohol, 2-8% of erythritol, 1.5-3% of carrageenan, 0.08-0.5% of lutein ester, 0.003-0.01% of lutein, 0.2-3% of acerola cherry powder, 0.2-3% of raspberry powder, 0.2-3% of blueberry juice powder, 0.1-2% of a grape seed extract, 0.3-6% of food essence and 0.5-5% of a compound coating agent. According to the invention, the blueberry lutein soft sweets have very strong health-care effects of relieving asthenopia and improving eyesight, so that the lutein ester health-care soft sweets are simple and feasible health-care foods with definite effects for people with asthenopia, people with age-related visual macular degeneration and common people needing to supplement lutein.

The invention relates to a novel micromolecule phentriazine dioxin-like compound and a medicine by taking compound as active ingredient, and the application of the compound which is used as endothelial growth factor inhibitors for treating fundus oculi maculopathy. The micromolecule phentriazine dioxin-like compound is expressed by a general formula (A) or a general formula (B). The compound is used as an active ingredient of the medicine, can selectively block one group of kinase of vascular endothelial growth factor, and performs important functions of treating macular degeneration such as retina effusion, angiogenesis and inflammation mediated by the vascular endothelial growth factor ; in addition, the medicine can be designed into a drug administration way that eye medicine is dropped in eye, thereby improving the safety, convenience and universality of medicine usage.

The invention belongs to the field of Chinese medicine and particularly relates to an extraction process of lanostane-type triterpene and application of lanostane-type triterpene in preparation of medicaments for inhibiting angiogenesis. The extraction process has the advantages that the new application of a triterpenoid obtained from hedge euphorbia is provided. It is shown by experiments that the triterpenoid has an obvious inhibition effect on HUVEC migration and arterial rings of rats. It is indicated that the triterpenoid has angiogenesis resistance activity and can serve as an angiogenesis inhibitor applied to treatment of neovascularization dependence and neovascularization-related diseases such as tumors, arthritis, macular disease and atherosclerosis.

The invention discloses a preparation method of a nutritional cake. The method comprises the following steps: a, weighing selected rice, glutinous rice, coarse cereals and tea in parts by weight; b, putting the weighed rice, glutinous rice and coarse cereals into water for soaking, and then taking the rice, glutinous rice and coarse cereals out of the water for airing; c, putting the soaked rice,glutinous rice and coarse cereals into a crusher for crushing, then taking and measuring purified water for heating, wherein the heating temperature is 90-100 DEG C, and putting the weighed tea into hot water for soaking; and d, putting the crushed rice, glutinous rice and coarse cereals into a mixer for mixing. A tomato juice is added, has rich vitamins, alkaline elements, cellulose and pectin, and is rich in lycopene. The lycopene is a stronger antioxidant, can improve age-related macular disease, reduces the incidence of cancer and coronary heart disease, improves the digestion of proteins,and reduces bloating and food indigestion.

The invention relates to the field of image recognition and digital medical treatment, and discloses an eye fundus image-based lesion detection method and device, computer equipment and a storage medium, and the method comprises the steps: obtaining an eye fundus screening image which comprises a scanning image and a contrast image; inputting the scanned image into a first network in a dual-channel network of a deep learning network model, and obtaining a first image feature obtained by the first network; the first image feature comprises fundus curvature and reflectivity; inputting the contrast image into a second network in a dual-channel network of a deep learning network model, and obtaining a second image feature obtained by the second network; the second image feature comprises blood vessel density and fundus tissue thickness; fusing the first image feature and the second image feature to obtain a fused feature; and matching a maculopathy grade corresponding to the image according to the fusion feature. According to the invention, the accuracy of fundus macular degeneration grade identification can be improved.

The invention discloses a method for segmenting a myopia macular lesion area in a retina OCT image based on an improved U-shaped network, and the method comprises the steps: building a network structure which comprises an encoder module, a feature aggregation pooling module FAPM, a decoder module and a deep supervision module, wherein the feature aggregation pooling module FAPM is arranged in an encoder channel of the encoder module and used for down-sampling and aggregating global context information and local information, and the deep supervision module is arranged in each layer, except a bottom layer, of the decoder and used for guiding a network to generate a feature map with higher representativeness, in an experiment, the output of the network structure is verified by adopting a joint segmentation task of RBCC damage and myopia traction streak lesion areas in an optical coherence tomography OCT image. According to the method for segmenting the myopia macular lesion area in the retina OCT image based on the improved U-shaped network, automatic segmentation of RBCC damage and myopia traction lines in the retina OCT image is achieved, and the small target segmentation performance is improved.

The invention discloses a highland barley smut recognition method, and belongs to the field of image processing. The method comprises the following steps of converting the preprocessed image into an HSV color space, setting an H and S division level and a change range, counting the H and S component data in the image according to a setting result, creating a histogram, and normalizing the height of the histogram of the image. Respectively calculating a clustering center of the positive sample and a clustering center of the negative sample according to the histogram and the corresponding label;Wherein the detection images are used for respectively calculating the distances between the detection images and positive and negative sample clustering centers, and classifying the detection imagesand a class with a relatively close distance into a class; According to the method, the images of normal highland barley leaves and the highland barley leaves with the macular disease can be well classified by filtering and denoising the images, extracting color space characteristics and normalizing the color space characteristics, and the identification efficiency and accuracy of the highland barley macular disease are improved.

The invention relates to a traditional Chinese medicine composition for treatment, which is characterized in that the parts by weight of the raw materials are as follows: 2-4 parts of catechu, 4-6 parts of Morus alba, 6-9 parts of calcined gypsum, and 6-9 parts of rehmannia glutinosa , Sophora flavescens 4-6 parts, Eclipta 6-9 parts, Bamboo ginseng 6-9 parts, Rush 6-9 parts, Cloth leaves 6-9 parts, Saponin thorn 4-6 parts, Purple pearl leaves 6 parts ~8 parts, 6-9 parts of Poria. The beneficial effects of the traditional Chinese medicine of the present invention are: clearing heat and cooling blood, removing dampness and relieving itching, dispersing the lungs and removing freckles, diverting water and infiltrating dampness, strengthening the spleen and calming the heart. It is effective for both acute and chronic macular diseases.

Disclosed is an agent for inhibiting or reducing light sensitivity comprising a substance that inhibits or reduces ubiquitination, for example, an agent for inhibiting or reducing light sensitivity capable of protecting a retina, reducing retinal degeneration, reducing aging of a retina and/or reducing hyperesthesia. The present invention is suitable for use in amelioration or prevention of a symptom associated with light reception, such as age-related macular degeneration, retinitis pigmentosa, Leber congenital amaurosis, Stargardt disease, cone-rod dystrophy, diabetic retinopathy, macular edema, retinal ischemia, photosensitive seizure, photosensitive epilepsy, psychiatric disorders, photic maculopathy, asthenopia, retinal dysfunction, sleep disorders, migraine and light-induced damage.

The invention discloses an effect evaluation kit for anti-vascular endothelial growth factor drugs treating wet age-related macular degeneration diseases. The kit includes optional related reagents for detection of VEGFA gene rs943080 variation. The invention also discloses application of VEGFA gene rs943080 variation in preparation of effect evaluation reagents for anti-vascular endothelial growth factor drugs treating wet age-related macular degeneration diseases. The kit provided by the invention can evaluate the treatment effect of anti-vascular endothelial growth factor drugs on wet age-related macular degeneration diseases, and plays an important role in treatment of wet age-related macular diseases.